港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

医药外包概念

1,443.509

-372.390-20.51%

涨家数：- -

跌家数：8

平家数：- -

市盈率：- -

高：1,774.879

开：1,774.879

低：1,436.026

收：1,815.898

数据加载中...

港股异动 | CRO概念股跌幅居前机构称关税对CXO及上游目前影响较为有限关注生物安全法案相关进展

恒指日内跌幅扩大至10%，恒生科技指数跌11.8%，药明生物(02269.HK)跌超20%。

康龙化成股价重挫14.20% 市值跌6.19亿港元

维亚生物股价重挫13.17% 市值跌4.83亿港元

方达控股盘中异动早盘大幅下挫12.00%

金斯瑞生物科技盘中异动急速下挫10.00%

泰格医药盘中异动股价大跌8.73%

药明生物股价重挫15.49% 市值跌147.45亿港元

昭衍新药股价重挫10.18% 市值跌1.38亿港元

【沛嘉医疗：完成ReachTactile机器人辅助TAVR系统首次人体临床试验】沛嘉医疗公告，公司完成ReachTactile机器人辅助经导管主动脉瓣置换（TAVR）系统首次人体临床试验的首例患者治疗。手术由厦门大学附属心血管病医院的王焱教授及其团队完成，利用ReachTactile™机器人辅助TAVR系统为一名重度主动脉瓣狭窄患者植入TaurusElite®经导管主动脉瓣膜。ReachTactile是公司内部研发的机器人辅助TAVR系统，为TAVR治疗提供创新、高性价比的解决方案。

半年内套现46亿！药明康德三度减持药明合联高位抛售成为业绩“止血贴”？

深圳商报·读创

过敏性鼻炎治疗研究取得新进展

业绩陡降泰格医药困在“周期”里

中国经营网

智通AH统计|4月4日

药明合联业绩与股价狂飙、药明康德却三度减持 2025年D&M资本支出将翻番或是重要原因

每日经济新闻

中国生物制药：“TQB6411 (EGFR/c-Met双抗ADC)”临床试验申请获CDE受理

中国生物制药(01177)研发的抗肿瘤药“TQB2101 (ROR1 ADC)”获得NMPA的临床试验默示许可

中华交易服务香港生物科技指数下跌1.75%，前十大权重包含药明生物等

每日卖空追踪 | 泰格医药 04月03日卖空量成交26.73万股，卖空比例为11.86%

先分拆上市后高位套现，起底药明康德的资本“炼金术”

环球老虎财经app

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/BK1576/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1576","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","market":"HK","secType":"PLATE","nameCN":"医药外包概念","latestPrice":1443.5087,"timestamp":1743998399963,"preClose":1815.8982,"halted":0,"volume":216327348,"delay":0,"changeRate":-0.205072,"floatShares":0,"shares":0,"eps":0,"marketStatus":"午间休市","change":-372.389526,"latestTime":"04-07 12:00:00","open":1774.8788,"high":1774.8788,"low":1436.026,"amount":4055221721,"amplitude":0.186603,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1744002000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1743989400000,1743998400000],[1744002000000,1744012800000]],"pbRate":2.250114,"peRate":11.036581,"turnoverRate":0.019043,"increases":0,"decrements":8,"flats":0,"marketCap":313858456064,"floatMarketCap":134408008704},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","high":1774.8788,"amplitude":0.186603,"preClose":1815.8982,"low":1436.026,"pbRate":"2.250114","latestPrice":1443.5087,"volume":216327348,"delay":0,"open":1774.8788,"prevYearClose":1395.7731,"prevWeekClose":1815.898,"prevMonthClose":1941.338,"prevQuarterClose":1941.338,"fiveDayClose":1942.366,"twentyDayClose":1793.042,"sixtyDayClose":1294.998,"secType":"PLATE","market":"HK","turnoverRate":0.019043,"peRate":11.036581,"marketCap":313858456064,"floatMarketCap":134408008704,"timestamp":1743998399963,"nameCN":"医药外包概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1576\",,,,undefined,":{"bkCode":"BK1576","up":0,"down":8,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1576\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2525036363","title":"港股异动 | CRO概念股跌幅居前 机构称关税对CXO及上游目前影响较为有限 关注生物安全法案相关进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2525036363","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525036363?lang=zh_cn&edition=fundamental","pubTime":"2025-04-07 10:03","pubTimestamp":1743991390,"startTime":"0","endTime":"0","summary":"本次美国对中国加征关税中，药品暂不涉及。该行指出，国内CXO行业目前在研发阶段主要以研发服务形式对美出口，属于免关税。国内“对等关税”出台预计同样对行业整体影响较小。西南证券指出，CXO关注生物安全法案相关进展。中泰国际此前表示，美国在今年出台的《2025财年国防授权法案》中暂未提及生物安全法案，根据近期在医药行业的多方了解，按目前情况预计2025年内出台生物安全法案的可能性不高。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1274420.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03347","03759","BK1141","BK1576","BK1583","CXO","01873","06127"],"gpt_icon":0},{"id":"2525038315","title":"恒指日内跌幅扩大至10%，恒生科技指数跌11.8%，药明生物(02269.HK)跌超20%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2525038315","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525038315?lang=zh_cn&edition=fundamental","pubTime":"2025-04-07 09:47","pubTimestamp":1743990473,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU0456846285.SGD","BK1521","LU0359202008.SGD","LU0516422366.SGD","LU0823426308.USD","LU0043850808.USD","IE00B0JY6N72.USD","02833","LU0140636845.USD","SG9999002562.SGD","SG9999002463.SGD","HSI","LU2039709279.SGD","LU0320764599.SGD","LU0039217434.USD","LU0417516902.SGD","LU0572944931.SGD","BK1576","BK4614","BK1610","LU0708995583.HKD","LU0348735423.USD","LU1242518857.USD","LU0307460666.USD","LU0051755006.USD","HSTECH","LU1794554557.SGD","LU1720050803.USD","02269","LU0052750758.USD","LU0516422440.USD","LU0181495838.USD","LU1880383366.USD","YANG","BK1141","HSImain","MHImain","LU1688375341.USD","MCHmain","513600","LU0516423174.USD","LU0819121731.USD","LU0456827905.SGD","LU0856984785.SGD","HHImain","LU1242518931.SGD","LU0516423091.SGD","LU0417516738.SGD","LU0823426480.USD","LU0348825331.USD"],"gpt_icon":0},{"id":"2525905632","title":"康龙化成股价重挫14.20% 市值跌6.19亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2525905632","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525905632?lang=zh_cn&edition=fundamental","pubTime":"2025-04-07 09:39","pubTimestamp":1743989989,"startTime":"0","endTime":"0","summary":"2025年04月07日早盘09时39分，康龙化成股票出现波动，股价急速下挫14.20%。截至发稿，该股报13.540港元/股，成交量457.69万股，换手率1.56%，振幅5.20%。资金方面，该股资金流入1606.36万港元，流出3204.21万港元。康龙化成股票所在的药品行业中，整体跌幅为1.94%。其相关个股中，华控康泰、衍生集团、中生联合涨幅较大，振幅较大的相关个股有德琪医药-B、亿胜生物科技、和黄医药，振幅分别为12.62%、12.60%、9.59%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025040709394994cd9e83&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025040709394994cd9e83&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1576","BK1141","03759"],"gpt_icon":0},{"id":"2525036389","title":"维亚生物股价重挫13.17% 市值跌4.83亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2525036389","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525036389?lang=zh_cn&edition=fundamental","pubTime":"2025-04-07 09:30","pubTimestamp":1743989437,"startTime":"0","endTime":"0","summary":"2025年04月07日早盘09时30分，维亚生物股票出现波动，股价快速下跌13.17%。截至发稿，该股报1.450港元/股，成交量13.2万股，换手率0.01%，振幅4.19%。资金方面，该股资金流入5.073万港元，流出5.6万港元。维亚生物股票所在的生物技术行业中，整体跌幅为8.07%。其相关个股中，中生北控生物科技、正大企业国际、中国抗体-B涨幅较大，振幅较大的相关个股有加科思-B、复宏汉霖、和铂医药-B，振幅分别为9.70%、9.68%、7.95%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025040709303797300bee&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025040709303797300bee&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1576","01873","BK1141"],"gpt_icon":0},{"id":"2525350230","title":"方达控股盘中异动 早盘大幅下挫12.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2525350230","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525350230?lang=zh_cn&edition=fundamental","pubTime":"2025-04-07 09:30","pubTimestamp":1743989434,"startTime":"0","endTime":"0","summary":"2025年04月07日早盘09时30分，方达控股股票出现波动，股价急速下跌12.00%。截至发稿，该股报1.100港元/股，成交量10000股，换手率0.00%，振幅0.00%。机构评级方面，在所有1家参与评级的机构中，100%的券商给予卖出建议，无券商给予买入、持有建议。方达控股股票所在的生物技术行业中，整体跌幅为8.07%。其相关个股中，中生北控生物科技、正大企业国际、中国抗体-B涨幅较大，振幅较大的相关个股有加科思-B、复宏汉霖、和铂医药-B，振幅分别为9.70%、9.68%、7.95%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025040709303494cd9a52&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025040709303494cd9a52&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01521","BK1141","BK1583","BK1576"],"gpt_icon":0},{"id":"2525035073","title":"金斯瑞生物科技盘中异动 急速下挫10.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2525035073","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525035073?lang=zh_cn&edition=fundamental","pubTime":"2025-04-07 09:30","pubTimestamp":1743989427,"startTime":"0","endTime":"0","summary":"2025年04月07日早盘09时30分，金斯瑞生物科技股票出现异动，股价急速跳水10.00%。截至发稿，该股报10.980港元/股，成交量150.6万股，换手率0.07%，振幅1.48%。机构评级方面，在所有13家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。金斯瑞生物科技股票所在的生物技术行业中，整体跌幅为8.07%。金斯瑞生物科技公司简介：金斯瑞生物科技股份有限公司是一家主要从事生物科学研究及相关业务的香港投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025040709302794cd9a3b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025040709302794cd9a3b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","HK0000306701.USD","01548","HK0000320223.HKD","HK0000320264.USD","HK0000306685.HKD","BK1583","BK1576"],"gpt_icon":0},{"id":"2525036621","title":"泰格医药盘中异动 股价大跌8.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2525036621","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525036621?lang=zh_cn&edition=fundamental","pubTime":"2025-04-07 09:30","pubTimestamp":1743989412,"startTime":"0","endTime":"0","summary":"2025年04月07日早盘09时30分，泰格医药股票出现异动，股价急速跳水8.73%。截至发稿，该股报27.700港元/股，成交量11.57万股，换手率0.09%，振幅2.31%。资金方面，该股资金流入3.961万港元，流出157.211万港元。泰格医药股票所在的生物技术行业中，整体跌幅为8.07%。其相关个股中，华康生物医学、中生北控生物科技、奥星生命科技涨幅较大，振幅较大的相关个股有复宏汉霖、和铂医药-B、药明合联，振幅分别为9.68%、6.23%、4.50%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025040709301297300bbd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025040709301297300bbd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1141","BK1576","03347"],"gpt_icon":0},{"id":"2525555036","title":"药明生物股价重挫15.49% 市值跌147.45亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2525555036","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525555036?lang=zh_cn&edition=fundamental","pubTime":"2025-04-07 09:30","pubTimestamp":1743989410,"startTime":"0","endTime":"0","summary":"2025年04月07日早盘09时30分，药明生物股票出现异动，股价急速下挫15.49%。截至发稿，该股报21.000港元/股，成交量305.55万股，换手率0.07%，振幅3.42%。资金方面，该股资金流入1386.76万港元，流出835.905万港元。药明生物股票所在的生物技术行业中，整体跌幅为8.08%。其相关个股中，华康生物医学、中生北控生物科技、奥星生命科技涨幅较大，振幅较大的相关个股有复宏汉霖、和铂医药-B、药明合联，振幅分别为9.68%、6.23%、4.50%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250407093010a4502477&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250407093010a4502477&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1589","IE00B0JY6N72.USD","LU0823426480.USD","LU0819121731.USD","LU0326950275.SGD","SG9999002562.SGD","LU1794554557.SGD","LU1242518857.USD","BK1521","LU0320764599.SGD","LU0043850808.USD","LU0708995583.HKD","LU1880383366.USD","LU0417516738.SGD","LU0456846285.SGD","LU1688375341.USD","02269","BK1610","LU0456827905.SGD","LU0039217434.USD","LU1720050803.USD","LU0823426308.USD","LU0359202008.SGD","LU0572944931.SGD","SG9999002463.SGD","LU0348735423.USD","LU0979878070.USD","LU1242518931.SGD","LU0588546209.SGD","BK1141","LU0348825331.USD","LU0051755006.USD","LU0516422366.SGD","LU0052750758.USD","LU0516422952.EUR","LU0359201612.USD","LU2039709279.SGD","LU0181495838.USD","LU0307460666.USD","LU0516423091.SGD","BK1576","LU0417516902.SGD","LU0516422440.USD","LU0516423174.USD","LU0327786744.USD","LU0856984785.SGD","LU0140636845.USD"],"gpt_icon":1},{"id":"2525903691","title":"昭衍新药股价重挫10.18% 市值跌1.38亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2525903691","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525903691?lang=zh_cn&edition=fundamental","pubTime":"2025-04-07 09:30","pubTimestamp":1743989406,"startTime":"0","endTime":"0","summary":"2025年04月07日早盘09时30分，昭衍新药股票出现波动，股价大幅下跌10.18%。截至发稿，该股报10.940港元/股，成交量5.2万股，换手率0.04%，振幅1.31%。资金方面，该股资金流入2.176万港元，流出21.3436万港元。最近的财报数据显示，该股实现营业收入21.80亿港元，净利润7,999.11万港元，每股收益0.11港元，毛利5.46亿港元，市盈率101.94倍。昭衍新药股票所在的生物技术行业中，整体跌幅为8.04%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025040709300697300b98&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025040709300697300b98&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1576","06127","BK1141"],"gpt_icon":0},{"id":"2525775606","title":"【沛嘉医疗：完成ReachTactile机器人辅助TAVR系统首次人体临床试验】沛嘉医疗公告，公司完成ReachTactile机器人辅助经导管主动脉瓣置换（TAVR）系统首次人体临床试验的首例患者治疗。手术由厦门大学附属心血管病医院的王焱教授及其团队完成，利用ReachTactile™机器人辅助TAVR系统为一名重度主动脉瓣狭窄患者植入TaurusElite®经导管主动脉瓣膜。ReachTactile是公司内部研发的机器人辅助TAVR系统，为TAVR治疗提供创新、高性价比的解决方案。","url":"https://stock-news.laohu8.com/highlight/detail?id=2525775606","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525775606?lang=zh_cn&edition=fundamental","pubTime":"2025-04-06 18:29","pubTimestamp":1743935387,"startTime":"0","endTime":"0","summary":"沛嘉医疗公告，公司完成ReachTactile机器人辅助经导管主动脉瓣置换（TAVR）系统首次人体临床试验的首例患者治疗。手术由厦门大学附属心血管病医院的王焱教授及其团队完成，利用ReachTactile™机器人辅助TAVR系统为一名重度主动脉瓣狭窄患者植入TaurusElite®经导管主动脉瓣膜。ReachTactile是公司内部研发的机器人辅助TAVR系统，为TAVR治疗提供创新、高性价比的解决方案。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/06182949326362.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1141","159891","BK1583","BK1576","03347"],"gpt_icon":0},{"id":"2525471327","title":"半年内套现46亿！药明康德三度减持药明合联 高位抛售成为业绩“止血贴”？","url":"https://stock-news.laohu8.com/highlight/detail?id=2525471327","media":"深圳商报·读创","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525471327?lang=zh_cn&edition=fundamental","pubTime":"2025-04-06 10:31","pubTimestamp":1743906682,"startTime":"0","endTime":"0","summary":"近日，国内CXO行业龙头企业药明康德（603259）发布公告称，4月1日，公司通过大宗交易继续出售所持有的药明合联5080万股股票，约占药明合联当前总股本的4.23%，成交金额约21.78亿港元（不包含手续费等交易费用），占公司最近一期（2024年度）经审计归属母公司股东净资产的3.43%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/news/1354,202504063365589431.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"eastmoney_highlight","symbols":["LU2045819591.USD","BK0216","LU2125910500.SGD","BK1141","02268","SG9999014674.SGD","LU2488822045.USD","LU1997245094.SGD","LU0456842615.SGD","LU2242644610.SGD","BK1583","LU1046422090.SGD","BK1576","LU0052750758.USD","LU0320764599.SGD","LU0708995583.HKD","02359","603259","LU1997245177.USD"],"gpt_icon":0},{"id":"2525796853","title":"过敏性鼻炎治疗研究取得新进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2525796853","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525796853?lang=zh_cn&edition=fundamental","pubTime":"2025-04-05 16:36","pubTimestamp":1743842214,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1583","BK0188","BK0146","BK1141","BK0236","000516","BK0077","03347","BK0096","BK0181","BK0042","BK0046","BK0114","BK1576"],"gpt_icon":0},{"id":"2525910756","title":"业绩陡降 泰格医药困在“周期”里","url":"https://stock-news.laohu8.com/highlight/detail?id=2525910756","media":"中国经营网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525910756?lang=zh_cn&edition=fundamental","pubTime":"2025-04-05 04:42","pubTimestamp":1743799328,"startTime":"0","endTime":"0","summary":"CRO（合同研究组织）行业难言“冬去春来”。近期，国内临床CRO龙头企业泰格医药（300347.SZ）披露了2024年财报。数据显示，公司全年营业收入为66.03亿元，同比下滑10.58%；归母净利润仅为4.05亿元，同比暴跌79.99%，创下自2018年以来的最低水平。泰格医药长期为全球药企提供临床试验管理服务，覆盖Ⅰ—Ⅳ期临床试验、数据管理、生物统计及注册申报等全方位内容。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504053365507418.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["03347","BK1576","BK1583","BK1141"],"gpt_icon":0},{"id":"2524276627","title":"智通AH统计|4月4日","url":"https://stock-news.laohu8.com/highlight/detail?id=2524276627","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524276627?lang=zh_cn&edition=fundamental","pubTime":"2025-04-04 16:15","pubTimestamp":1743754505,"startTime":"0","endTime":"0","summary":"智通财经APP数据显示，截止4月4日收盘，东北电气、弘业期货、浙江世宝分列AH溢价率前三位，溢价率分别为938.46%、355.13%、349.06%；招商银行、比亚迪股份、潍柴动力分列AH溢价率末三位，溢价率分别为14.17%、14.26%、19.45%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1274206.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BYDDY","03968","HPAD.SI","01375","01336","02465","00187","002594","02899","BK1576","601318","02238","02218","399300","81211","HYDD.SI","00042","01528","01330","01658","03145","00038","00107","03143","03678","03328","PNGAY","LU0164865239.USD","00995","01033","00553","00338","02068","02359","00568","159982","02338","01787","82318","06127","01057","00914","03606","01812","02727","01349"],"gpt_icon":1},{"id":"2524686260","title":"药明合联业绩与股价狂飙、药明康德却三度减持 2025年D&M资本支出将翻番或是重要原因","url":"https://stock-news.laohu8.com/highlight/detail?id=2524686260","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524686260?lang=zh_cn&edition=fundamental","pubTime":"2025-04-03 23:48","pubTimestamp":1743695297,"startTime":"0","endTime":"0","summary":"通过减持，药明康德总计回笼资金超45亿港元。药明康德披露减持后，药明合联股价连续2天下跌。药明康德预计，本次出售股票收益占2024年经审计归母净利润的比例超过10%，将影响公司今年上半年净利润约18.47亿元人民币。在今年初的JPM大会上，药明康德就对外宣布将进一步加速D&M阶段产能投入，预计2025年D&M资本支出将翻番，达到70亿到80亿元。此外，结合药明康德已经发布的2024年分红预案、2025年特别分红方案及回购方案，这些支出大约接近50亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250403234919972db805&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250403234919972db805&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1046422090.SGD","LU2488822045.USD","LU0052750758.USD","02268","LU2125910500.SGD","LU0708995583.HKD","LU0320764599.SGD","LU2242644610.SGD","BK1583","LU2045819591.USD","BK1576","02359","603259","BK1141","SG9999014674.SGD"],"gpt_icon":0},{"id":"2524264572","title":"中国生物制药：“TQB6411 (EGFR/c-Met双抗ADC)”临床试验申请获CDE受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2524264572","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524264572?lang=zh_cn&edition=fundamental","pubTime":"2025-04-03 22:58","pubTimestamp":1743692288,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 发布公告，本集团自主研发的“TQB6411 ”已向中国国家药品监督管理局药品评审中心提交临床试验申请，并获得受理。TQB6411是一种靶向EGFR、c-Met的抗体偶联药物，静脉注入血后抗体部分与肿瘤细胞表面 EGFR、c-Met结合阻断EGFR、c-Met信号通路，ADC经细胞内吞并转运到溶酶体，连接子经酶切后释放出DDDXD，导致DNA损伤和细胞死亡。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1274157.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ADC","BK4080","BK1589","BK1583","BK4017","03347","BK1515","CDE","BK4231","01177","BK1576","BK1521","BK1141","BK1191"],"gpt_icon":0},{"id":"2524261031","title":"中国生物制药(01177)研发的抗肿瘤药“TQB2101 (ROR1 ADC)”获得NMPA的临床试验默示许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2524261031","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524261031?lang=zh_cn&edition=fundamental","pubTime":"2025-04-03 22:53","pubTimestamp":1743692000,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药(01177)公布，该集团自主研发的“TQB2101 (ROR1 ADC)”已获得中国国家药品监督管理局(NMPA)的临床试验默示许可，拟用于治疗晚期恶性肿瘤。临床前研究数据显示，TQB2101在多种ROR1阳性肿瘤模型中展现出抗肿瘤活性，且具有良好的安全性特征。此次获批的I期临床试验将重点评估其在人体内的安全性、耐受性、药代动力学特性及初步疗效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1274155.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4231","03347","BK1515","BK1576","BK1589","BK1141","BK1191","01177","BK4080","BK1583","ADC","BK1521"],"gpt_icon":0},{"id":"2524266816","title":"中华交易服务香港生物科技指数下跌1.75%，前十大权重包含药明生物等","url":"https://stock-news.laohu8.com/highlight/detail?id=2524266816","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524266816?lang=zh_cn&edition=fundamental","pubTime":"2025-04-03 22:07","pubTimestamp":1743689261,"startTime":"0","endTime":"0","summary":"数据统计显示，中华交易服务香港生物科技指数近一个月上涨14.83%，近三个月上涨42.38%，年至今上涨38.47%。中华交易服务香港生物科技指数为证券价格指数，旨在反映于香港上市的生物科技公司的整体表现\"该指数以2014年12月12日为基日，以2000.0点为基点。从中华交易服务香港生物科技指数持仓样本的行业来看，医药卫生占比100.00%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/03220749291572.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU0516422440.USD","SG9999002463.SGD","LU0819121731.USD","LU0823426308.USD","BK1610","LU2039709279.SGD","LU0320764599.SGD","LU0456846285.SGD","IE00B0JY6N72.USD","BK1589","LU1880383366.USD","LU0327786744.USD","LU0326950275.SGD","LU0051755006.USD","LU1688375341.USD","LU0052750758.USD","LU0516422952.EUR","LU0456827905.SGD","LU0140636845.USD","LU1720050803.USD","LU0588546209.SGD","LU0359202008.SGD","LU0516423174.USD","LU1794554557.SGD","LU0856984785.SGD","LU0348825331.USD","LU0181495838.USD","02269","LU0708995583.HKD","LU0039217434.USD","LU0516423091.SGD","LU1242518931.SGD","LU0359201612.USD","BK1521","BK1576","LU0043850808.USD","BK1141","LU0572944931.SGD","159837","LU0979878070.USD","LU0307460666.USD","LU0417516738.SGD","SG9999002562.SGD","LU1242518857.USD","LU0516422366.SGD","LU0823426480.USD","LU0348735423.USD","LU0417516902.SGD"],"gpt_icon":1},{"id":"2524089265","title":"每日卖空追踪 | 泰格医药 04月03日卖空量成交26.73万股，卖空比例为11.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2524089265","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524089265?lang=zh_cn&edition=fundamental","pubTime":"2025-04-03 21:58","pubTimestamp":1743688720,"startTime":"0","endTime":"0","summary":"泰格医药北京时间04月03日，涨0.33%，卖空量成交26.73万股，较上一交易日减少23.45%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250403215845a6ae9efe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250403215845a6ae9efe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1576","BK1583","03347","BK1141"],"gpt_icon":0},{"id":"2524252037","title":"先分拆上市后高位套现，起底药明康德的资本“炼金术”","url":"https://stock-news.laohu8.com/highlight/detail?id=2524252037","media":"环球老虎财经app","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524252037?lang=zh_cn&edition=fundamental","pubTime":"2025-04-03 20:56","pubTimestamp":1743684960,"startTime":"0","endTime":"0","summary":"而在公司上市后，李革开始频繁减持旗下药明康德、药明生物等公司股票，累计获得超百亿财富。药明康德再施资本“炼金术”，从药明合联身上“薅”了46亿港元。关于减持原因，药明康德表示此次减持是为了公司的主业服务。半年内套现46亿港元药明康德半年内三度减持自己的控股公司。退市后，李革将药明康德的主业一分为三，分别为合全药业、药明生物、药明康德。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2025-04-03/doc-inerxarm1359215.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2488822045.USD","LU1046422090.SGD","LU2045819591.USD","LU0456842615.SGD","LU0052750758.USD","603259","LU1997245094.SGD","BK0216","BK1141","BK1583","LU2125910500.SGD","LU0320764599.SGD","BK1576","LU0708995583.HKD","LU2242644610.SGD","LU1997245177.USD","02359"],"gpt_icon":0}],"pageSize":20,"totalPage":12,"pageCount":1,"totalSize":222}]}}